Prostate cancer is a type of cancer that is developed in the prostate gland and it can spread by breaking away from prostate tumors. The prostate gland is found only in men and is located below the bladder. Adenocarcinomas, small cell carcinomas, neuroendocrine tumors (other than small cell carcinomas), transitional cell carcinomas, and sarcomas are a type of prostate cancer. Prostate cancer can be diagnosed by ultrasound, collecting a sample of prostate tissue, MRI fusion, and biopsy.
Rising cases of prostate cancer around the globe is a prime factor fueling market growth. According to the report published in April 2018, by "Our World in Data" in 2017, 9.6 million people are estimated to have died from the various forms of cancer. Every sixth death in the world is due to cancer, making it the second leading cause of death. Moreover, increasing the launch of innovative prostate cancer diagnostic devices is another major factor serving as a growth factor. For instance, in July 2019, Diagnostics developer MDNA Life Sciences has partnered with Aspire Pharma to introduce the new Mitomic Prostate Test (MPT) for clinical use in the UK. The blood test is intended to identify individuals with clinically significant prostate cancer or those who require treatment. It analyses mitochondrial DNA as biomarkers to determine whether a man has or does not have cancer.
From the geographical perspective, North America is expected to gain significant growth over the forecast period and this can be attributed to the high prevalence of prostate cancer in the region. According to the U.S. Department of Health and Human Services, in 2019, the number of new cases of prostate cancer was 174,650 and death case was approx. 31,620.
However, the high cost of the diagnosis and treatment of prostate cancer is expected to hamper the market growth.
Key Developments
• In September 2019, the Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic castration-sensitive prostate cancer (mCSPC).
• In October 2019, GE Healthcare has formed a global alliance with Theragnostics for the commercialization of a prostate-specific membrane antigen (PSMA) PET / CT imaging agent, GalliProst. The diagnostic is designed to help visualize prostate cancer, offering information on the status of the disease and allowing personalized treatment.
• In September 2019, Koelis SAS (“Koelis” or the “Company”) and InnovaHealth Partners, LP (“InnovaHealth”) jointly announced today along with Medevice Partners (“Medevice”). Koelis is a leading innovator in the market for image-guided systems for prostate cancer diagnosis and treatment.
World economic growth, the Prostate Cancer Diagnostics industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Prostate Cancer Diagnostics market size to maintain the average annual growth rate of 0.0506911866246 from 8200.0 million $ in 2014 to 10500.0 million $ in 2020, Stratagem Market Insights analysts believe that in the next few years, Prostate Cancer Diagnostics market size will be further expanded, we expect that by 2026, The market size of the Prostate Cancer Diagnostics will reach 14900.0 million $.
This Report covers the manufacturers' data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the World, which shows a regional development status, including market size, volume, and value, as well as price data.
Besides, the report also covers segment data, including type segment, industry segment, channel segment, etc. cover different segment market size, both volume, and value. Also cover different industries clients information, which is very important for the manufacturers. If you need more information,
Section 1: Definition
Section (2 3): Manufacturer Detail
Genomic Health
Abbott
OPKO
Siemens Healthcare
DiaSorin
BioMeriux
Roche
MDx Health
Beckman Coulter
Myriad Genetics
Ambry Genetics
Section 4: Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)
Section (5 6 7): Segmentation
Product Type Segmentation:
Tumor Biomarker Tests
Imaging
Biopsy
Industry Segmentation:
age < 55
age 55-75
age > 75
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2020-2026)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
Request Discount 
Inquire Before Buy
